The FDA-approved therapy for the treatment of Alpha-1-related lung disease, specifically emphysemaObstructive airway disease in which the walls of the alveoli (air sacs) are damaged or destroyed., is generally referred to as augmentation therapy. As currently available, augmentation therapy describes the use of human plasma-derived alpha-1 antitrypsin (AATalpha-1 antitrypsin) from healthy donors to supplement or augment the AATalpha-1 antitrypsin levels circulating in the blood and lungs of Alphas diagnosed with emphysemaObstructive airway disease in which the walls of the alveoli (air sacs) are damaged or destroyed.. The therapy is administered via a weekly intravenous infusion and, until other therapies become available, is considered ongoing and lifelong.
While augmentation therapy is considered the only specific therapy for Alpha-1 related lung disease, the treatment plan for lung-affected individuals with Alpha-1 should also include a variety of approaches such as the appropriate use of therapeutic antibiotics, an immunization program including viral hepatitis and influenza strains, reduction or elimination of environmental risks factors, appropriate inhaled medications, an exercise program, and oxygen, if needed.
What is Augmentation therapy? – Big Fat Reference Guide
Resources
- Augmentation Therapy – AlphaNet